Endocrine Abstracts

Polycystic ovary syndrome (PCOS) is one of the most prevalent endocrine disorder of women at reproductive-age and accounts for 80% of the causes of anovulatory infertility. Despite the widely characterized reproductive, endocrine, and metabolic abnormalities, the mechanisms underlying PCOS remain unclear. Thus, it is essential to identify novel biomarkers that will allow to disclosure novel pathways involved PCOS pathophysiology, which could then be used to improve PCOS manage...

Introduction: Evidence has suggested a relationship between female obesity and the outcomes of medically assisted reproduction techniques (MRT); however, the evidence regarding male obesity is still scarce and discordant. Aim: Evaluate the influence of female and male obesity on the results of MRT.Materials and methods: Retrospective analysis of 2159 couples, with and without obesity, submitted to the first treatment of medically a...

Introduction: Oestrogens and androgens modulate the effects of growth hormone (GH). Sex differences have been described in acromegaly, with conflicting results in different populations. Additionally, data on sex differences in tumour histopathology are scarce.Aims: To analyse the influence of sex and menopause status in tumour characteristics and surgical outcomes in patients with acromegaly.Materials and methods: Retrospective coh...

Introduction: Only <1% of cases of primary hyperparathyroidism (PHPT) occur during pregnancy. PHPT increases risk of complications such as miscarriage, premature birth and life-threatening maternal hypercalcemic crises. Hyperparathyroidism Jaw Tumor Syndrome (HPT-JT) is a rare inherited cause of PHPT, resulting from CDC73 gene mutations. There are a few reports described about HPT-JT in pregnancy. Although parathyroidectomy is the definite treatment for PHPT, given the sca...

Estrogen-producing adrenal gland tumors (EPAGT) are extremely rare, accounting for only 1–2% of all adrenal tumors. They are most commonly observed in men or in children, and are unusual in women. They are almost always malignant even if they seem benign at presentation, and most of them have a poor prognosis. We present a case of a 71-year-old man with painful bilateral gynecomastia, without galactorrhea, over 4 months. Markedly elevated plasma estradiol levels were foun...

Introduction: Hypocalcaemia is a potential post-thyroidectomy complication. Patients with previous Roux-en-Y Gastric Bypass (RYGBP) are at increased risk of symptomatic hypocalcaemia refractory to treatment. This complication is rare and there is not consensus on how to act.Clinic case: Female with 34 years old, with a history of Obesity (BMI 45.7 kg/m2), submitted to RYGBP in 2013, with a total loss of 47 kg (current BMI 27.3 kg/m2...

Introduction: The hyperthyroidism is a risk factor for tachyarrhythmia and dilated cardiomyopathy. Amiodarone is an effective antiarrhythmic medication, however if coexisting thyroid pathology complicates the treatment of thyroid dysfunction. It presents a case of Graves’ disease (GD) of long evolution, which illustrates the complexity of these associations. Clinical case: man, 44 years old, smoker, history of acute myocardial infarction and GD diagnosed at age 28. Has ma...

Introduction: Clinical inertia applied to type2 Diabetes Mellitus (T2DM) treatment, is defined as a lack of treatment’s intensification of patients who are not in HbA1c target. Clinical inertia leads to a postponement of new therapeutic introduction, with all complications associated with a poor metabolic control. In Portugal there are only studies that show good or poor metabolic control but do not mention clinician’s attitude towards these values. Recently publishe...

Introduction: The SGLT-2 inhibitors (InibSGLT2) are the newest class of non-insulin antidiabetic drugs (ANI) for type 2 diabetes mellitus (T2DM) treatment. Currently is only available in Portugal, dapagliflozin. This pharmacological class have shown benefits in metabolic control (reduction of 0.5–0.8% HbA1c) and in weight loss (1–3 kg).Objective: Evaluate the impact of InibSGLT2 in patients with T2DM followed in a Diabetes department.<p cla...

Introduction: American Thyroid Association recommends that benign thyroid nodules should be revaluated 6–18 months after initial FNA and in case of stability the follow-up should be 3–5 years. However there isn’t any consensus about the periodicity of the follow-up.Aim: To evaluate the nodules in terms of function, size and malignancy in a 10-year follow-up.Methods: Retrospective study of 347 patients (543 benign thy...